ArticleFrontiers in immunology2026
NeoThy™ immune-humanized mice can produce anti-drug antibodies to support immunogenicity assessment for biological drug products.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Introduction: Assessment of immunogenicity for new therapeutic protein products and biosimilars is an important aspect of drug development and the safety evaluation process. Conventional animal models typically do not reliably predict immunogenicity, as the human drug is seen as foreign in the animal model. To address this need, we conducted a proof-of-concept study with neonatal thymus (NeoThy™) immune-humanized mice using drug products known to have higher rates of immunogenicity in patients. NeoThy immune-humanized mice develop a fully engrafted human immune system that includes a human thymus for proper T cell development capable of recognizing human versus foreign proteins. Objective: This study used infliximab and interferon-beta (IFN-β) as monotherapies and in combination to determine if NeoThy immune-humanized mice could produce specific adaptive immune responses to the drugs. Methods: NeoThy immune humanized mice were generated at two different locations, creating six experimental groups. Mice received infliximab, IFN-β, a combination of infliximab and IFN-β, positive or negative control with treatment schedule appropriate to the therapeutic. Peripheral blood/serum was collected on day 0, 21, 42, and 63; tissues (bone marrow, spleen, lymph nodes) were harvested at necropsy (day 63). Immune reconstitution and treatment effects were assessed with flow cytometry, proliferation, total IgM/IgG isotyping, anti-drug antibodies (ADA) ELISAs for infliximab and IFN-β, and histopathology. Results: NeoThy immune-humanized mice showed broad and ample human immune reconstitution with donor-dependent differences noted. We observed immune activation and B cell class switching including IgG Conclusions: NeoThy immune-humanized mice mount human-like, donor-dependent immune responses to biologics, including class switching, antigen-specific proliferation, and ADA formation. These preliminary findings suggest that NeoThy immune-humanized mice have the biological ability to help assess immunogenicity risk, and other immunosafety considerations for biological drug products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.